Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status:
Completed
Trial end date:
2015-04-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Patients with Stage IIIC and Stage IV
Melanoma experience benefit when treated with Denileukin diftitox in two different dosing
schedules.